KPTI
What one share of Karyopharm Therapeutics holds
Pharmaceutical Preparations
We are a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer.
Karyopharm Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $7.55 |
|---|---|
| Profit | −$11.58 |
| Cash and investments | $2.42 |
| Book value | −$14.56 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.06 | −$43.80 | $0.03 | −$33.76 | — | $58.10 |
| 2017 | $0.52 | −$42.15 | $0.02 | −$24.11 | — | $39.21 |
| 2018 | $8.01 | −$47.13 | $0.62 | −$42.66 | — | $45.17 |
| 2019 | $9.90 | −$48.32 | $0.05 | −$46.25 | — | $11.42 |
| 2020 | $22.50 | −$40.87 | $0.03 | −$33.39 | — | $10.26 |
| 2021 | $41.84 | −$24.75 | $0.04 | −$21.40 | — | −$15.78 |
| 2022 | $28.78 | −$30.28 | $0.02 | −$27.42 | — | −$2.21 |
| 2023 | $19.17 | −$18.79 | $0.00 | −$12.17 | — | −$17.78 |
| 2024 | $17.18 | −$14.00 | $0.02 | −$15.10 | — | −$22.11 |
| 2025 | $13.36 | −$17.93 | $0.00 | −$6.89 | — | −$16.00 |